Compass Pathways reports 6-month data from second psilocybin Phase 3 trial
Tweet Send to a Friend
Compass Pathways plc (Nasdaq: CMPS) released 26-week results from its second Phase 3 clinical trial, COMP006, of COMP360, a synthetic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
